首页 News 正文

Roche's $3.1 billion investment layout: another pharmaceutical giant enters the weight loss drug market

网事大话每
1293 0 0

Analysts estimate that the global weight loss market will reach a size of up to $100 billion. Swiss pharmaceutical giant Roche recently announced that it has agreed to acquire unlisted American weight loss drug developer Carmot Therapeutics for an initial price of $2.7 billion. This means that it entered the weight loss drug market by acquiring "Fast Track", challenging weight loss drug giants Novo Nordisk and Lilly. Roche stated that according to the trading contract, the transaction is expected to be completed in the first quarter of 2024. If Carmot Therapeutics achieves individual milestones with its drugs, the company's shareholders can receive $400 million.
Multiple giants are intensifying their layout in the weight-loss drug market
After the transaction is completed, Roche will acquire all current clinical and preclinical assets of Carmot Therapeutics, and employees of Carmot Therapeutics will also join Roche's pharmaceutical department. For Roche, this transaction marks the company's return to the GLP-1 field. Previously, in 2018, Roche abandoned the GLP-1 field when its subsidiary sold a patent for an experimental drug to Lilly for a prepayment of $50 million.
It is reported that Carmot Therapeutics is an American biotechnology company in the clinical stage. Last month, Carmot Therapeutics just submitted its prospectus for listing on NASDAQ and is now being acquired by Roche. Public information shows that Carmot Therapeutics is committed to the development of metabolic disease drugs. At present, the company's products include subcutaneous and oral incretin drugs, which help to treat obesity in diabetes and non diabetes patients and multiple preclinical plans.
In the second half of this year, there were frequent acquisition transactions in the weight loss drug market. In July of this year, Lilly acquired the unlisted Versanis for up to $1.93 billion to further expand its weight loss drug product line; Last month, AstraZeneca agreed to purchase exclusive rights to the development and commercialization of oral GLP-1 weight loss products produced by Chinese biotech company Eccogene for up to $2 billion.
Weight loss pills are selling well, and Novo Nordisk's net profit increased by 43% year-on-year in the first half of the year
Novo Nordisk's previously released financial report for the first half of 2023 showed that during the reporting period, its net sales were 107.667 billion Danish kroner, compared to 83.296 billion Danish kroner in the same period last year, a year-on-year increase of 29%; The net profit was 39.242 billion Danish kroner, compared to 27.528 billion Danish kroner in the same period last year, an increase of 43% year-on-year. Novo Nordisk has raised its annual profit and sales expectations. The CEO of the company said in a statement that Novo Nordisk had raised its annual performance forecast based on the strong demand of the market for diabetes and obesity drugs. The company now serves more patients than ever before.
From the perspective of product line, the sales of diabetes and obesity care increased by 36% to DKK 99 billion, of which the sales of diabetes drug GLP-1 increased by 49%, and the sales of obesity care drugs surged by 158% to DKK 18.1 billion.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  •   据媒体报道,OpenAI正准备推出一款代号为“Operator”的全新AI助理产品,可以自动执行各种复杂操作,包括编写代码、预订旅行、自动电商购物等。根据内部员工爆料,OpenAI领导层预计将在2025年1月发布该产品,首 ...
    永远的希望
    昨天 11:06
    支持
    反对
    回复
    收藏
  • 【小摩辣评“特朗普2.0”:关税大棒料打击经济、重燃通胀!】摩根大通资产管理公司(JPMorgan Asset Management)首席全球市场策略师David Kelly周三表示,当选总统特朗普激进的关税计划,可能会减缓全球经济,并给 ...
    besharp
    昨天 12:37
    支持
    反对
    回复
    收藏
  •   本报讯 (记者李豪悦)11月12日,腾讯音乐娱乐集团(以下简称“腾讯音乐”)宣布其截至2024年9月30日止第三季度的未经审计财务业绩。   2024年第三季度,腾讯音乐娱乐集团业绩表现稳健,总收入为70.2亿元,同 ...
    覃志辉
    3 天前
    支持
    反对
    回复
    收藏
  •   新华财经上海11月13日电芯片制造商英伟达和软银集团的电信部门软银公司周三表示,两家公司已经试运行了全球首个人工智能和5G电信网络。   两家公司表示,该网络可以同时运行人工智能和5G工作负载,这一过程被 ...
    惡魔獵人
    前天 12:36
    支持
    反对
    回复
    收藏
网事大话每 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    3